Written in SCIENCE he
He COVID-19 came to change our lives during the 2020, 2021 and part of 2023well this world pandemiche collected the life of millions of people in all the Worldbut not only during this time, but the consequences continued to take their toll and claim souls some time later, as some experienced chronic diseasesothers suffered because diseases that already suffered became complicated, fortunately another one was only left with small traces of this disease, of which they have not yet been able to fully recover. One of these cases is the loss of smell and the tastebut at least now they have medicines to deal with these issues.
In accordance with research made by scientists In various parts of the world, the antiviral pill called Ensitrelvir is known to help reduce the duration of two symptoms caused by the virus. COVID-19 become shorter and we refer to the loss of smell and pleasure when eatingsince many people still recover them in their entirety and try to lead their lives a little calmly, although this has made it very difficult for them.
Once the pandemic COVID-19 It started 3 years ago, between 40% and 50% of infected people who experienced these two issues they could consume the antiviral medication molnopiravirwhich made these symptoms disappear, unfortunately it was very strong and only patients in critical condition They could consume them, the rest had to endure them.
Some countries like Japan They have already made ensitrelvir available to the public, since last year it received the emergency approval and citizens with mild symptoms Moderates can make use of it. It should be noted that the creator of this drug He is Japanese and continues to perform clinical trials in order to find even more benefits and reduce the harm or risks it may represent.
“Most people eventually recover on their own, but we know that some people have had long-term problems with smell and taste,” said Shionogi, who owns the company. When the Omicron variants became dominant, loss of taste and smell began to be less and less common,” says Amesh Adalja, an infectious disease specialist at the Johns Hopkins Center for Health Security in Baltimore, Maryland.